Clairvoyant Therapeutics

Clairvoyant Therapeutics is a trailblazing biotechnology startup dedicated to revolutionizing global mental health through psilocybin therapy. The company aims to provide evidence-based psychedelic therapy to patients with Alcohol Use Disorder (AUD), facilitating healthier and more enriched lives and stronger communities.

Founded in 2021, Clairvoyant Therapeutics boasts a team with a proven clinical track record and extensive drug development experience, positioning it as the 2nd most advanced psilocybin drug development company globally. The company's strategic mission focuses on expediting the introduction of psilocybin therapy in the EU, UK & Canada by 2026.

Currently conducting a placebo-controlled, randomized, double-blind Phase 2b clinical study across 15 sites in Canada and the EU, Clairvoyant is anticipated to be a pioneer in the field.

The startup recently secured a Seed Round investment on 07 July 2022 from Origin Therapeutics (CSE: ORIG), solidifying its position and potential impact in the Biotechnology and Pharmaceutical industries from its headquarters in Canada. With its innovative approach and promising developments, Clairvoyant Therapeutics is poised to make significant strides in addressing mental health challenges through pioneering psychedelic therapy.